Gastro Hep Advances, Journal Year: 2024, Volume and Issue: 3(8), P. 1148 - 1156
Published: Jan. 1, 2024
Language: Английский
Journal of Hepatology, Journal Year: 2024, Volume and Issue: 81(3), P. 492 - 542
Published: June 7, 2024
Language: Английский
Citations
296
Obesity Facts, Journal Year: 2024, Volume and Issue: 17(4), P. 374 - 444
Published: Jan. 1, 2024
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty (NAFLD), is defined as (SLD) in the presence of one or more cardiometabolic risk factor(s) and absence harmful alcohol intake. The spectrum MASLD includes steatosis, metabolic steatohepatitis (MASH, NASH), fibrosis, cirrhosis MASH-related hepatocellular carcinoma (HCC). This joint EASL-EASD-EASO guideline provides an update on definitions, prevention, screening, diagnosis treatment for MASLD. Case-finding strategies with using non-invasive tests, should be applied individuals factors, abnormal enzymes, and/or radiological signs hepatic particularly type 2 diabetes (T2D) obesity additional factor(s). A stepwise approach blood-based scores (such FIB-4) and, sequentially, imaging techniques transient elastography) suitable to rule-out/in advanced which predictive liver-related outcomes. In adults MASLD, lifestyle modification - including weight loss, dietary changes, physical exercise discouraging consumption well optimal management comorbidities use incretin-based therapies (e.g. semaglutide, tirzepatide) T2D obesity, if indicated advised. Bariatric surgery also option obesity. If locally approved dependent label, non-cirrhotic MASH significant fibrosis (stage ≥2) considered a MASH-targeted resmetirom, demonstrated histological effectiveness acceptable safety tolerability profile. No pharmacotherapy can currently recommended cirrhotic stage. Management adaptations drugs, nutritional counselling, surveillance portal hypertension HCC, transplantation decompensated cirrhosis.
Language: Английский
Citations
56
The Lancet. Gastroenterology & hepatology, Journal Year: 2024, Volume and Issue: 9(10), P. 944 - 956
Published: Sept. 4, 2024
Language: Английский
Citations
34
The Lancet, Journal Year: 2024, Volume and Issue: 404(10464), P. 1761 - 1778
Published: Nov. 1, 2024
Language: Английский
Citations
28
Journal of Hepatology, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 1, 2024
Language: Английский
Citations
22
Journal of Hepatology, Journal Year: 2024, Volume and Issue: 81(2), P. 326 - 344
Published: June 6, 2024
Language: Английский
Citations
20
Nature Reviews Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: 21(9), P. 626 - 645
Published: June 7, 2024
Most patients with alcohol-associated liver disease (ALD) engage in heavy drinking defined as 4 or more drinks per day (56 g) 8 (112 week for women and 5 (70 15 (210 men. Although abstinence from alcohol after diagnosis of ALD improves life expectancy reduces the risk decompensation disease, few studies have evaluated whether treatment use disorders will reduce progression improve liver-related outcomes. In November 2021, National Institute Alcohol Abuse Alcoholism commissioned a task force that included hepatologists, addiction medicine specialists, statisticians, clinical trialists members regulatory agencies to develop recommendations design conduct trials evaluate effect use, particularly eliminate ALD. The conducted extensive reviews relevant literature on Findings were presented at one in-person meeting discussed over next 16 months final recommendations. As directly address this topic, 28 approved by all represent consensus expert opinions. Alcohol-associated is main cause morbidity mortality globally. This Consensus Statement makes design, best practice effects disorder.
Language: Английский
Citations
20
Journal of Hepatology, Journal Year: 2024, Volume and Issue: 81(2), P. 345 - 359
Published: March 28, 2024
The rising prevalence of liver diseases related to obesity and excessive use alcohol is fuelling an increasing demand for accurate biomarkers aimed at community screening, diagnosis steatohepatitis significant fibrosis, monitoring, prognostication prediction treatment efficacy. Breakthroughs in omics methodologies the power bioinformatics have created excellent opportunity apply technological advances clinical needs, instance development precision personalised medicine. Via technologies, biological processes from genes circulating protein, as well microbiome - including bacteria, viruses fungi, can be investigated on axis. However, there are important barriers omics-based biomarker discovery validation, semi-quantitative measurements untargeted platforms, which may exhibit high analytical, inter- intra-individual variance. Standardising methods need validate them across diverse populations presents a challenge, partly due disease complexity dynamic nature expression different stages. Lack validity causes lost opportunities when studies fail provide knowledge needed regulatory approvals, all contributes delayed translation these discoveries into practice. While no matured implementation, extent data generated has enabled hypothesis-free plethora candidate that warrant further validation. To explore many hepatologists detailed commonalities differences between various layers, both advantages approaches.
Language: Английский
Citations
16
Liver International, Journal Year: 2024, Volume and Issue: 44(8), P. 1762 - 1767
Published: April 10, 2024
A recent Delphi consensus proposed a new definition for metabolic dysfunction associated steatotic liver disease (MASLD) and introduced entity called MetALD, condition in which (SLD), moderate alcohol intake coexist. Given the limited available data on prognostic implications of these entities, we performed systematic review meta-analysis cohort studies to evaluate association MASLD MetALD with hard clinical outcomes. We included 5 total 9 824 047 participants. Compared participants without SLD, increased rates all-cause mortality incident cardiovascular were present both MetALD. Moreover, was also significantly higher risks cancer-related (n = 2 studies, random-effects HR 2.10, 95% CI 1.35-3.28) 3 1.17, 1.12-1.22). Although preliminary, evidence indicates more unfavourable prognosis patients compared those MASLD.
Language: Английский
Citations
16
Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 17, 2025
ABSTRACT Background The current subclassification of steatotic liver disease (SLD) relies on validated questionnaires, such as Alcohol Use Disorders Identification Test (AUDIT) and Lifetime Drinking History (LDH), which, while useful, are impractical lack precision for their use in routine clinical practice. Phosphatidylethanol (PEth) is a quantitative, objective alcohol biomarker with high sensitivity specificity. Aims To assess the diagnostic accuracy PEth differentiating metabolic dysfunction alcohol‐associated (MetALD) from dysfunction‐associated (MASLD) large, population‐based, prospective, multiethnic cohort individuals overweight or obesity. Methods This cross‐sectional analysis prospective study including 374 adults obesity residing Southern California who had SLD defined by MRI‐PDFF ≥ 5%. research visit included medical history, biochemical testing, standardised questionnaires (including AUDIT LDH), physical examination, advanced imaging using MRE. Results Among SLD, prevalence MASLD, MetALD, ALD was 90.1%, 6.4%, 3.5%, respectively. robust detection MetALD (AUROC 0.81, 95%CI 0.73–0.89) Youden cut‐off 25 ng/mL. In head‐to‐head comparative efficacy analysis, both statistically clinically superior to all previously used indirect biomarkers diagnosing aspartate aminotransferase/alanine aminotransferase ratio, mean corpuscular volume, gamma glutamyltransferase, ALD/NAFLD index ( p < 0.05). Conclusions outperforms non‐invasive tests MASLD has potential change practice enhancing SLD.
Language: Английский
Citations
8